Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Seres Therapeutics (MCRB) PT Lowered to $17 at Oppenheimer
August 3, 2018 9:25 AM EDTOppenheimer lowered its price target on Seres Therapeutics (NASDAQ: MCRB) to $17.00 (from $18.00) while maintaining a Outperform rating.
... MoreSeres Therapeutics (MCRB) Misses Q2 EPS by 5c, Revenues Miss
August 2, 2018 7:20 AM EDTSeres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.68), $0.05 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $4.6 million versus the consensus estimate of $6.57 million.
Seres has made excellent progress across our deep pipeline of early and late, clinical and preclinical stage microbiome programs,... More
